Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences ...

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...

The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional ...

Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory ...

Gilead is withdrawing the accelerated approval for its blockbuster antibody-drug conjugate Trodelvy for bladder cancer after ...

Trodelvy in locally advanced or metastatic urothelial cancer ... urothelial cancer, a type of bladder cancer, according to a study. In the TROPHY-U-01 trial published in the Journal of Clinical ...

Trodelvy can help improve survival rates for people with some types of breast cancer and bladder cancer. It can also help prevent certain quality of life factors from becoming worse. This article ...

With its lead candidate in a phase 3 trial for a rare eye cancer, Aura Biosciences is looking to expand the drug into a more ...

Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer. Mere months after ...

Cancer Screening Guidelines Validated for Dermatomyositis Most of the cancers were detected using standard age- and sex-based cancer screenings, suggesting the potential for overscreening in this ...